Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Mar 18:13:840580.
doi: 10.3389/fendo.2022.840580. eCollection 2022.

A Case Series of Ketoacidosis After Coronavirus Disease 2019 Vaccination in Patients With Type 1 Diabetes

Affiliations
Case Reports

A Case Series of Ketoacidosis After Coronavirus Disease 2019 Vaccination in Patients With Type 1 Diabetes

Fumiyoshi Yakou et al. Front Endocrinol (Lausanne). .

Abstract

Introduction: We report a case series of severe ketoacidosis after COVID-19 vaccination in a type 1 diabetes patients treated with insulin and an SGLT-2 inhibitor.

Case report: We present two cases of type 1 diabetes mellitus. One patient was treated with insulin therapy and an SGLT-2 inhibitor, and the other patient was treated with insulin therapy alone. Both patients became ill after coronavirus disease-2019 vaccination, making it difficult to continue their diet or insulin injections. On admission, they developed severe diabetic ketoacidosis. This is the first report of ketoacidosis after coronavirus disease-2019 vaccination.

Conclusion: The vaccine should be carefully administered to type 1 diabetes patients receiving intensive insulin therapy and a sodium-glucose transporter due to the high risk ketoacidosis. It is important to instruct patients to drink sufficient fluids and to continue insulin injections when they become sick.

Keywords: clinical diabetes; coronavirus disease 2019 vaccination; ketoacidosis; latent autoimmune diabetes in adults; sodium-glucose cotransporter 2 inhibitor; type 1 diabetes.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
The course in day1-2 in a patient with ketoacidosis who was treated with insulin and SGLT2 inhibitor. PG, plasma glucose.
Figure 2
Figure 2
The course in day1-2 in a patient with ketoacidosis who was treated with insulin. PG, plasma glucose.

References

    1. Federica B, Francesca D, Matteo P, Federico B, Mattia B, Luca B, et al. . Practical Considerations for the Management of Cushing's Disease and COVID-19: A Case Report. Front Endocrinol (Lausanne) (2020) 11:554. doi: 10.3389/fendo.2020.00554 - DOI - PMC - PubMed
    1. Zhang JJY, Lee KS, Ang LW, Leo YS, Young BE. Risk Factors for Severe Disease and Efficacy of Treatment in Patients Infected With COVID-19: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis. Clin Infect Dis (2020) 71(16):2199–206. doi: 10.1093/cid/ciaa576 - DOI - PMC - PubMed
    1. Shimabukuro T, Nair N. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine. JAMA (2021) 325(8):780–1. doi: 10.1001/jama.2021.0600 - DOI - PMC - PubMed
    1. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. . Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med (2020) 383(27):2603–15. doi: 10.1056/NEJMoa2034577 - DOI - PMC - PubMed
    1. Yamada T, Shojima N, Noma H, Yamauchi T, Kadowaki T. Sodium-Glucose Co-Transporter-2 Inhibitors as Add-on Therapy to Insulin for Type 1 Diabetes Mellitus: Systematic Review and Meta-Analysis of Randomized Controlled Trials. Diabetes Obes Metab (2018) 20(7):1755–61. doi: 10.1111/dom.13260 - DOI - PubMed

Publication types

MeSH terms